Yesterday an advisory joint committee at the U.S. Food & Drug Administration voted to reject Nektar's application for its new non-addictive opioid NKTR-181. The thinking--my thinking--was that the committee had structured the vote so that the most likely outcome was a narrow approval of the drug candidate that required further clinical trials by Nektar. Nope. […]
To subscribe to JAM you need to fill in some details below including, ahem, some info on how you'll pay us. A subscription is $199 (although if you're subscribing with one of our special offers it will be lower) for a year for ongoing and continuing access to the site. And we'll throw in the first week free! If you change your mind during that first week, just cancel your subscription from your profile page, and you won't be billed anything.